Abstract: The present invention provides a method for preparing a pharmaceutical composition of a pharmaceutical ingredient (API) which is loaded on a carrier and stabilized therethrough. In particular, the present invention relates to a composition of a poorly soluble nanoparticulated API on a carrier in the dry state and which is processed as pharmaceutical formulation of said API with improved release profile and bioavailability.

Abstract: The present invention relates to the use of spray-dried sorbitol, such as Parteck® SI, as plasticizer for polymer containing compositions processed by (hot) melt extrusion. Due to its improved properties, achieved by its special manufacturing process (spray drying), this direct compressible excipient shows more additional benefits than the same substance in crystalline state.

Abstract: For manufacturing a solid administration form comprising at least one active pharmaceutical ingredient, a flowable but setting composite material comprising the at least one active pharmaceutical ingredient is added together and set to generate the solid administration form. The flowable composite material is liquefied and delivered to a discharge unit. Small portions of liquefied composite material are intermittently discharged through an outlet into a setting unit. The flowable composite material comprises a polymer and at least one active pharmaceutical ingredient dispersed or dissolved within the polymer. The small portions are droplets and the solid administration form is generated by adding droplets that stick together before or during the setting of the liquefied composite material. An average diameter of the droplets can be less than 350 ?m. There can be a void space between at least some small portions, resulting in a porous structure of the solid administration form.

Abstract: An extrudable polyvinyl alcohol (PVA) powder with improved flowability containing particles of PVA, which has been cryo-milled, and which has d50 particle sizes in the range of 45 to 1400 ?m; or which has a particle size distribution of d10=20±10 ?m, d20=30±10 ?m, d50=70±10 ?m, d90=200±30 ?m, and d99=300±30 ?m; and a powdery composition for the preparation of pharmaceutical formulations which contains the polyvinyl alcohol homogeneously mixed with at least one active pharmaceutical ingredient (API); and a process for producing a solid pharmaceutical dosage form by extruding or forming a homogeneous melt of a mixture of ingredients containing the powdered polyvinyl alcohol and at least one active pharmaceutical ingredient (API), and forming a powder or a molded form.

Abstract: The present invention relates to compacted glycine granules, where at least 75% of the granules have a particle size of above 0.7 mm, and to a process for the preparation and use of granules of this type.

Abstract: The present invention relates to the use of an amino sugar as plasticizer in formulations comprising a polymer as carrier for active ingredients, in particular for compositions which are intensively mixed by treatment in a melt extrusion and then formulated by suitable post-treatment.

Abstract: The present invention relates to novel pharmaceutical formulations which have controlled, delayed release of active ingredient, and to a process for the preparation of such formulations. The invention additionally relates to the use of these novel pharmaceutical administration forms as medicaments for the treatment of diseases which require delayed release of the active ingredient, such as hypertension, or asthmatic diseases.

Abstract: The present invention relates to the use of spray-dried sorbitol, such as Parteck® SI, as plasticizer for polymer containing compositions processed by (hot) melt extrusion. Due to its improved properties, achieved by its special manufacturing process (spray drying), this direct compressible excipient shows more additional benefits than the same substance in crystalline state.

Abstract: The present invention relates to novel pharmaceutical formulations which have controlled, delayed release of active ingredient, and to a process for the preparation of such formulations. The invention additionally relates to the use of these novel pharmaceutical administration forms as medicaments for the treatment of diseases which require delayed release of the active ingredient, such as hypertension, or asthmatic diseases.

Abstract: The present invention relates to the use of an amino sugar as plasticizer in formulations comprising a polymer as carrier for active ingredients, in particular for compositions which are intensively mixed by treatment in a melt extrusion and then formulated by suitable post-treatment.

Abstract: The present invention relates to an improved powdered polyvinyl alcohol (PVA), which can be used for pharmaceutical products, and that due to its improved properties can be better dosed during formulation processes.

Abstract: The present invention relates to compacted glycine granules, where at least 75% of the granules have a particle size of above 0.7 mm, and to a process for the preparation and use of granules of this type.

Abstract: The present invention relates to novel pharmaceutical formulations which have controlled, delayed release of active ingredient, and to a process for the preparation of such formulations. The invention additionally relates to the use of these novel pharmaceutical administration forms as medicaments for the treatment of diseases which require delayed release of the active ingredient, such as hypertension, or asthmatic diseases.

Abstract: The present invention refers to a method for producing storage-stable solid dispersions of poorly soluble pharmaceutically active compounds comprising polyvinyl alcohol as carrier matrix. The invention also refers to the prepared compositions and their use.

Abstract: The present invention relates to formulations having extended release of active ingredient, comprising an active ingredient from BCS Class I having high solubility and high permeability in a polyvinyl alcohol-containing matrix, from which the active ingredient is released at a controlled rate over a therapeutically relevant time period independently of the composition of the release medium.

Abstract: The present invention relates to a process for producing inorganic particulate material, the material obtainable by such process, a modified release delivery system comprising the material and the use of the material for the administration of a bioactive agent.

Abstract: The present invention relates to pharmaceutical formulations of active ingredients which have low solubility in aqueous solutions, having improved release of active ingredient, and to a process for the preparation thereof. In particular, these are pharmaceutical preparations in which magnesium hydroxide carbonate serves as excipient.

Abstract: The present invention is directed to the use of a composite silicon oxide-based material for the modified release of biologically active agents.

Abstract: The present invention relates to solid formulations which contain at least one porous carrier and one or more functional substances in a stable mixture, and to the use thereof.

Abstract: The present invention provides a rapidly disintegrating pharmaceutical formulation in the form of a coated tablet having increased mechanical strength, or hardness. The invention furthermore relates to a process for the production of the coated tablet and to the use of these formulations.